As we have seen from TACTI that when pembrolizumab is combined eftilagimod in cancers independent PD-L1 status there are significant responses in both NSCLC and HNSCC.
The trillion dollar question is this response limited to NSCLC and HNSCC or does the combination of these two agents work across the cancer disease spectrum? Does it work in breast cancer?
In August 2021 Seeking alpha reported:
Immutep’s Chinese partner, EOC Pharma to start another trial for licensed cancer candidate
(NASDAQ:IMMP) is trading ~3.0% higher in the pre-market after the company announced that EOC Pharma, its Chinese partner for eftilagimod alpha, is planning to start a clinical trial for the drug in combination with anti-PD-1 therapy.The trial expected to start in H1 2022 builds on data presented by Immutep (IMMP) for eftilagimod alpha at ASCO 2021 and EOC’s Phase 2 trial designed to test the treatment in combination with chemotherapy in metastatic breast cancer.The previously announced mid-stage study is expected to start in H2 2021.With exclusive licensing rights, EOC is solely responsible for the development and commercialization of eftilagimod alpha in Greater China. Immutep is entitled to receive milestone payments and sales-based royalties.Do we have any updates on this? Is pembrolizumab the PD1 inhibitor that EOC is going to use?
Ann: New & significant data from AIPAC phase 2b trial in MBC, page-26
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.5¢ |
Change
0.005(1.56%) |
Mkt cap ! $465.4M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 33.0¢ | 31.8¢ | $394.8K | 1.219M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 21 | 415370 | 32.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.5¢ | 143601 | 29 |
View Market Depth
| Last trade - 12.44pm 14/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |